bg-szy NK Cell Therapy Agent
The NK Cell Therapy Agent provides AI-driven design and optimization of natural killer cell therapies for cancer treatment. It covers CAR-NK engineering, cytokine-induced memory-like (CIML) NK generation, KIR/HLA matching, and NK cell expansion optimization.
When to Use This Skill
- When designing CAR-NK constructs for tumor targeting.
- To optimize KIR/HLA mismatch for allogeneic NK therapy.
- For generating memory-like NK cells with enhanced persistence.
- When predicting NK cell activation against specific tumor types.
- To analyze NK cell receptor repertoires and function.
Core Capabilities
CAR-NK Design: Design chimeric antigen receptors optimized for NK cell biology (NK-specific signaling domains).
KIR/HLA Matching: Predict KIR-HLA interactions for donor selection in allogeneic therapy.
Memory-Like NK Generation: Optimize CIML protocol with IL-12/15/18 cytokine preactivation.
Expansion Optimization: ML models for feeder-free NK expansion conditions.
Tumor Target Prediction: Match NK receptor profiles to tumor ligand expression.
Persistence Enhancement: Engineering strategies for improved in vivo survival.
NK Cell Advantages Over T Cells
| Feature | NK Cells | T Cells |
|---|---|---|
| MHC requirement | No | Yes |
| Allogeneic use | Yes (no GVHD) | Limited (GVHD risk) |
| CRS risk | Lower | Higher |
| Off-the-shelf | Yes | Autologous typical |
| Antigen escape | Multiple receptors | Single CAR |
| Persistence | Shorter | Longer |
CAR-NK Architecture
[scFv] - [Hinge] - [Transmembrane] - [Costimulatory] - [Signaling]
NK-Optimized Domains:
- Transmembrane: NKG2D, CD8α, or CD28
- Costimulatory: 2B4, DAP10, or CD28
- Signaling: CD3ζ (with NK-specific adaptations)
- Additional: Cytokine secretion (IL-15), suicide switch
Workflow
Input: Target antigen, tumor type, NK source (PB, UCB, iPSC, cell line).
CAR Design: Generate optimized CAR-NK construct sequence.
KIR Analysis: Determine KIR genotype and HLA matching for donors.
Activation Protocol: Optimize cytokine cocktail for desired phenotype.
Expansion: Design feeder-based or feeder-free expansion protocol.
Quality Prediction: Predict NK product functionality.
Output: CAR sequence, donor recommendations, expansion protocol, QC metrics.
Example Usage
User: "Design a CAR-NK targeting CD19 for B-cell malignancies with enhanced persistence."
Agent Action:
python3 Skills/Immunology_Vaccines/NK_Cell_Therapy_Agent/nk_designer.py \
--target CD19 \
--tumor_type b_cell_lymphoma \
--nk_source ucb \
--persistence_strategy il15_secretion \
--costimulatory 2B4_DAP10 \
--donors donor_hla_kir.json \
--output carnk_design/
NK Receptor-Ligand Interactions
Activating Receptors:
| Receptor | Ligands | Tumor Expression |
|---|---|---|
| NKG2D | MICA/B, ULBPs | Stress-induced |
| DNAM-1 | CD155, CD112 | Broadly expressed |
| NKp30 | B7-H6, BAG6 | Tumor-specific |
| NKp46 | Unknown tumor | Variable |
| CD16 | IgG Fc | ADCC trigger |
Inhibitory Receptors:
| Receptor | Ligands | Function |
|---|---|---|
| KIR2DL1 | HLA-C2 | Self tolerance |
| KIR2DL2/3 | HLA-C1 | Self tolerance |
| KIR3DL1 | HLA-Bw4 | Self tolerance |
| NKG2A | HLA-E | Checkpoint |
Memory-Like NK (CIML) Protocol
Cytokine Preactivation:
- IL-12 (10 ng/mL) + IL-15 (50 ng/mL) + IL-18 (50 ng/mL)
- 16-18 hour stimulation
- Enhanced IFN-γ, cytotoxicity upon restimulation
- Improved in vivo persistence
Clinical Evidence: Effective in relapsed/refractory AML
KIR/HLA Matching Optimization
Missing-Self Recognition:
- Donor KIR + / Patient HLA -
- Enhanced NK cytotoxicity
- Important for allo-HSCT
Prediction Model:
- Input: Donor KIR genotype, patient HLA
- Output: Predicted NK alloreactivity score
- Validated in transplant outcomes
AI/ML Components
CAR-NK Optimization:
- Adapted CARMSeD for NK biology
- NK-specific signaling domain preferences
- Tonic signaling prediction
Expansion Prediction:
- Fold-expansion from culture conditions
- Phenotype shift modeling
- Exhaustion marker prediction
Prerequisites
- Python 3.10+
- HLA/KIR databases
- NK receptor databases
- Flow cytometry analysis tools
Related Skills
- CART_Design_Optimizer_Agent - For CAR engineering principles
- Epitope_Prediction_Agent - For target selection
- Flow_Cytometry_AI - For NK phenotyping
Clinical Development
Current CAR-NK Programs:
- CD19 CAR-NK (MD Anderson - AML, lymphoma)
- NKG2D CAR-NK (various solid tumors)
- CD70 CAR-NK (renal cell carcinoma)
- HER2 CAR-NK (breast cancer)
Author
AI Group - Biomedical AI Platform